Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.

[1]  M. Foster,et al.  Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1 , 2018, Orphanet Journal of Rare Diseases.

[2]  D. Barbouth,et al.  Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy. , 2018, Blood cells, molecules & diseases.

[3]  Yuyu Feng,et al.  Clinical and molecular characteristics of patients with Gaucher disease in Southern China. , 2018, Blood cells, molecules & diseases.

[4]  J. Ibrahim,et al.  A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration. , 2018, Blood cells, molecules & diseases.

[5]  J. Szer,et al.  Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy. , 2018, Blood cells, molecules & diseases.

[6]  P. Mistry,et al.  Therapeutic position of eliglustat. , 2017, Blood cells, molecules & diseases.

[7]  S. Packman,et al.  Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial , 2017, American journal of hematology.

[8]  M. Pedroso,et al.  Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. , 2017, Blood.

[9]  J. Ibrahim,et al.  Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry , 2016, Molecular genetics and metabolism reports.

[10]  J. Fletcher,et al.  Interruption of enzyme replacement therapy in Gaucher disease. , 2016, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[11]  M. Balwani,et al.  Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial , 2015, The Lancet.

[12]  J. Stirnemann,et al.  Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1 , 2015, Orphanet Journal of Rare Diseases.

[13]  S. Packman,et al.  Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. , 2015, JAMA.

[14]  Pilar Giraldo,et al.  A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. , 2014, Blood cells, molecules & diseases.

[15]  P. Svenningsson,et al.  Impact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher Disease Type 3 , 2014, Archivum Immunologiae et Therapiae Experimentalis.

[16]  J J Swen,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapy.

[17]  Laurie D. Smith,et al.  Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase , 2013, American journal of hematology.

[18]  A. Mehta,et al.  Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. , 2011, Blood.

[19]  D. Elstein,et al.  Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. , 2011, Blood cells, molecules & diseases.

[20]  J. Fletcher,et al.  Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia. , 2011, Blood cells, molecules & diseases.

[21]  P. Bonate,et al.  A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. , 2010, Blood.

[22]  B. Bembi,et al.  Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. , 2010, Blood cells, molecules & diseases.

[23]  Y. Eto,et al.  Clinical and genetic study of Japanese patients with type 3 Gaucher disease. , 2009, Molecular genetics and metabolism.

[24]  P. Kaplan,et al.  A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. , 2009, Molecular genetics and metabolism.

[25]  P. Mistry,et al.  Life expectancy in Gaucher disease type 1 , 2008, American journal of hematology.

[26]  S. Packman,et al.  Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: An analysis of 798 patients from the ICGG Gaucher Registry , 2008, Journal of Inherited Metabolic Disease.

[27]  S. van Weely,et al.  Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. , 2007, Blood.

[28]  S. Packman,et al.  Imiglucerase (Cerezyme®) improves quality of life in patients with skeletal manifestations of Gaucher disease , 2007, Clinical genetics.

[29]  V. Solano,et al.  Quality of life related to type 1 Gaucher disease: Spanish experience , 2005, Quality of Life Research.

[30]  G. Andria,et al.  Therapeutic goals in the treatment of Gaucher disease. , 2004, Seminars in hematology.

[31]  P. Kaplan,et al.  Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. , 2002, The American journal of medicine.

[32]  R. Dwek,et al.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis , 2000, The Lancet.

[33]  K. Sims,et al.  Quality of life assessment in adults with type 1 Gaucher disease , 1999, Quality of Life Research.

[34]  A. Damiano,et al.  The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study , 1998, Quality of Life Research.

[35]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[36]  J. Ibrahim,et al.  Two-year postmarketing safety experience with oral eliglustat in adults with type 1 Gaucher disease , 2017 .

[37]  B. Bembi,et al.  Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients. , 2013, JIMD reports.

[38]  G. Grabowski,et al.  Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the world. , 2007, Molecular genetics and metabolism.

[39]  R. Schiffmann,et al.  Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources , 1995, Annals of Internal Medicine.